 "Dr Reddy's completes acquisition of product portfolio from Teva")
Dr Reddy’s Laboratories Ltd has launched bupropion HCl extended-release tablets (SR) in strength of 100 mg, 150 mg and 200 mg in the US following its approval by the US Food & Drug Administration (FDA). The new product is a therapeutic equivalent generic version of GSK’s Wellbutrin SR (sustained-release) tablet, which is a medication primarily used as an antidepressant and smoking cessation aid.
The Wellbutrin SR brand and generic had US sales of approximately $109.6 million MAT for the most recent twelve months ending in July 2016, according to IMS Health.
Dr Reddy’s buproprion SR tablets are available in 100 mg, 150 mg and 200 mg, in bottle count sizes of 60, 100 and 500.
